What is the 13F Pro Quality Score for FENC?

13F Pro ranks FENNEC PHARMACEUTICALS INC. (FENC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FENC's current score at https://13fpro.ai/research/FENC (free sign-up required for the full ranking).

Where does 13F Pro source FENC data?

All FENNEC PHARMACEUTICALS INC. fundamentals and ownership data come directly from SEC EDGAR. FENNEC PHARMACEUTICALS INC. files with the SEC under CIK 1211583. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FENC in?

FENNEC PHARMACEUTICALS INC. (FENC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FENC research updated on 13F Pro?

FENC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FENNEC PHARMACEUTICALS INC.(FENC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1211583 FENC stock profile & AI dashboard →

13F Pro Quality Score

33.9/100

Rank #2,218 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

96.6/100

Profitability

22.3/100

Balance Sheet

21.3/100

Earnings Quality

30.0/100

Free Cash Flow

19.7/100

Institutional Flow

7.5/100

Revenue Scale

10.1/100

Dilution Risk

11.8/100

FENC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for FENNEC PHARMACEUTICALS INC. (FENC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FENC at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,218 of 2,879 stocks — the bottom half of the AI-ranked universe. FENC scores in the top quartile across revenue growth (96.6). Areas of concern include institutional flow (7.5) and revenue scale (10.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), FENNEC PHARMACEUTICALS INC. reports quarterly revenue of $15.1M, net income of $201.0K, free cash flow of $2.4M. Top institutional holders of FENC by reported 13-F value include Rosalind Advisors,, Southpoint Capital Advisors, Solas Capital Management,, based on the most recent SEC filings. FENC trades on the Nasdaq exchange and files with the SEC under CIK 1211583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FENC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FENNEC PHARMACEUTICALS INC. directly from SEC EDGAR. FENNEC PHARMACEUTICALS INC.'s 13F Pro composite quality score has ranged between 13 and 60 since 2025, currently 33.9 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about FENNEC PHARMACEUTICALS INC.

Quirks, history, and lore behind FENC — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap specialty pharmaceutical company · listed on Nasdaq · headquartered in New York.
2
The Numbers
Annual revenue in the low tens of millions — this is a commercial-stage biotech with a very focused, single-product pipeline rather than a sprawling drug portfolio.
3
The History
Founded in Canada and later redomiciled to the U.S., the company spent years pursuing FDA approval for a drug to protect pediatric cancer patients from a brutal chemotherapy side effect.
4
The Secret
Its lead drug targets ototoxicity — the hearing loss caused by cisplatin chemotherapy in children — a niche so overlooked that no approved treatment existed for decades.
5
The Lore
Its flagship product, sodium thiosulfate, is a compound known since the 19th century, yet the company figured out how to get it FDA-approved as a named drug for kids with cancer.
6
The Giveaway
The company's name evokes a small, clever North American canid — fitting for a tiny pharma firm that quietly won approval for PEDMARK, the first therapy to prevent hearing loss in pediatric cisplatin patients.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$15.1M

Net Income

Q1 2026

$201.0K

Free Cash Flow

Q1 2026

$2.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$21.3MFY 2023

FY19 $0.00FY20 $170.0KFY21 —FY23 $21.3M

Net Income

+7.5% YoY

$-16.0MFY 2023

FY19 $-12.8MFY20 $-18.1MFY21 $-17.3MFY23 $-16.0M

Operating Income

+25.8% YoY

$-12.8MFY 2023

FY19 $-13.0MFY20 $-17.9MFY21 $-17.2MFY23 $-12.8M

EPS (Diluted)

+10.4% YoY

$-0.60FY 2023

FY19 —FY20 $-0.76FY21 $-0.67FY23 $-0.60

Total Assets

+19.9% YoY

$26.9MFY 2023

FY19 $14.1MFY20 $31.4MFY21 $22.4MFY23 $26.9M

Total Debt

+518.6% YoY

$30.9MFY 2023

FY19 —FY20 —FY21 $5.0MFY23 $30.9M

Op. Cash Flow

-20.5% YoY

$-17.1MFY 2023

FY19 $-9.1MFY20 $-15.6MFY21 $-14.2MFY23 $-17.1M

Metric	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$21.3M	—	$170.0K	$0.00	$0.00	$0.00
Net Income	$-16.0M +7.5%	$-17.3M +4.2%	$-18.1M -41.8%	$-12.8M -29.2%	$-9.9M -40.3%	$-7.0M
Operating Income	$-12.8M +25.8%	$-17.2M +3.7%	$-17.9M -37.5%	$-13.0M -25.0%	$-10.4M -49.7%	$-7.0M
EPS (Diluted)	$-0.60 +10.4%	$-0.67 +11.8%	$-0.76	—	—	—
Total Assets	$26.9M +19.9%	$22.4M -28.7%	$31.4M +122.1%	$14.1M -38.4%	$22.9M -19.2%	$28.4M
Total Debt	$30.9M +518.6%	$5.0M	—	—	—	—
Operating Cash Flow	$-17.1M -20.5%	$-14.2M +8.8%	$-15.6M -72.1%	$-9.1M -15.8%	$-7.8M -114.9%	$-3.6M

Get alerted when FENC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FENNEC PHARMACEUTICALS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FENC

Rosalind Advisors, Inc.
$17.9M2,908,201 sh
Southpoint Capital Advisors LP
$16.9M2,744,741 sh
Solas Capital Management, LLC
$15.3M2,482,198 sh
AIGH Capital Management LLC
$12.2M1,981,501 sh
BlackRock, Inc.
$8.4M1,368,176 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M897,144 sh
AWM Investment Company, Inc.
$4.4M720,135 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.3M371,738 sh
STATE STREET CORP
$2.2M359,055 sh
Potomac Capital Management, Inc.
$1.4M224,400 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$17.9M	2,908,201
Southpoint Capital Advisors LP	$16.9M	2,744,741
Solas Capital Management, LLC	$15.3M	2,482,198
AIGH Capital Management LLC	$12.2M	1,981,501
BlackRock, Inc.	$8.4M	1,368,176
VANGUARD CAPITAL MANAGEMENT LLC	$5.5M	897,144
AWM Investment Company, Inc.	$4.4M	720,135
GEODE CAPITAL MANAGEMENT, LLC	$2.3M	371,738
STATE STREET CORP	$2.2M	359,055
Potomac Capital Management, Inc.	$1.4M	224,400

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FENC on your watchlist

Track score changes the day FENNEC PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FENC a good stock to buy?

13F Pro's AI-powered analysis of FENNEC PHARMACEUTICALS INC. (FENC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FENC are available on the FENC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FENC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FENC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FENNEC PHARMACEUTICALS INC.'s investment landscape.